

5 June 2025

Annual General Meeting – Presentation and Addresses

Enlitic, Inc. (ASX: ENL) (“the Company”) attaches a copy of the Chair address and presentation to be made at today’s Annual General Meeting of the Company.

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries:

Enlitic Investor Relations

Australia:

invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

Read more at enlitic.com.

Chairman's Address

At Enlitic, we are seeking to address a significant issue in the healthcare industry: the growing data volumes which are unstandardized, fragmented and under-utilised. This issue significantly compromises data quality and also impacts healthcare organisations' ability to deliver care to their patients. The products we bring to market are industry-leading and help address these problems.

Research has shown that AI-enabled analysis tools are reducing diagnosis time by up to 30%. Our software framework uses AI to create a network between our clients' applications which facilitates better communication and enables their data to be more useful, more accurate and more efficient – this ultimately provides better care for patients. The increasing demand for data imaging in healthcare markets and the soaring data volumes associated with this drives the need for our products that are already commercially available through our Ensign 2.0 framework, components of which were delivered ahead of schedule in mid 2024.

Frequent data migrations are essential for staying current with technological advancements but often introduce challenges. Our recent acquisition of Laitek also provides us with the ability to address our client's need for safe, efficient and accurate migration of healthcare imaging data. Our data migration capabilities have been shown to significantly reduce costs and timelines as they transfer data 5 – 10 times faster than traditional methods, resulting in better outcomes for our customers and their patients.

We are committed to advancing intelligent data frameworks and driving innovation and growth for the healthcare industry.

We aim to empower healthcare professionals in a number of different ways to drive better patient outcomes, including:

- Providing them with high quality data to make accurate assessments and improve patient outcomes;
- Providing them with advanced tools and strategies to implement complex data migrations and allow them to stay current with innovations;
- Improving their data management practices and drive operational efficiency; and
- Facilitating value creation from their medical imaging and data migration through data standardisation, anonymisation, validation and migration.

As the healthcare landscape continues to evolve, providers must harness advanced data and medical imaging technologies to deliver more effective and personalised care, and we are well placed to support healthcare providers on this journey.

Our superior product offering was validated with the recently announced partnership with GE Healthcare, the largest deal done in Enlitics history, which can bring in up to \$A50m of revenue into Enlitic over the next 5 years. With all these positive developments, I understand shareholders frustration over the languishing price of our CDIs, which is partly a function of broader markets and partly the idiosyncratic risk within the business which we are actively addressing. Namely, as a board, we are focused on achieving profitability to enable a sustainable business and continue to deliver strong partnerships, like GE, as well as deliver long term value to shareholders.

ENLITIC, INC.

AI DRIVEN DATA MANAGEMENT FOR
THE MEDICAL IMAGING SECTOR

Annual General Meeting

5 June 2025



Important Notice and Disclaimer

This presentation has been prepared by Enlitic, Inc. (Enlitic or the Company) to provide summary information about the Company and its associated entities as at the date of this presentation, and the information in this presentation remains subject to change without notice. The Company has no obligation to update or correct this presentation.

The presentation is for informational purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or the law of any other jurisdiction. The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) and is not intended to be used as the basis for making an investment decision.

No representation or warranty, express or implied, is made as to the currency, accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. None of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers (each a Limited Party) guarantees or makes any representations or warranties, express or implied, as to, or takes responsibility for, the currency, accuracy, reliability, completeness or fairness of this presentation or the information, opinions and conclusions contained in this presentation. The Company does not represent or warrant that this presentation is complete or that it contains all material information about the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any expenses, damages, costs or loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation, including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

None of the Company or any of the other Limited Parties act, or are responsible, as a fiduciary to you, your directors, officers, employees, affiliates, partners, representatives, consultants, agents, advisers, securityholders, creditors or any other person. You and each of the Company and the other Limited Parties expressly disclaim any fiduciary relationship. The Company and the other Limited Parties are relying on you complying with this important notice and disclaimer and on the truth and accuracy of the representations, warranties, undertakings and acknowledgments given by you.

This presentation may contain certain forward-looking statements, forecasts, estimates, projections and comments about future events, including the Company's beliefs, assumptions and expectations about the performance of its businesses and certain strategic transactions and the recovery of domestic and global airline booking levels. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "goals", "aims", "target" and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward-looking statements will not be achieved. A number of important factors, both known and unknown, could cause the Company's actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, and many of these factors are beyond the Company's control. As such, there can be no assurance that actual outcomes will not differ materially from these statements. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and their differences may be material. Any forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. As such, no undue reliance should be placed on any forward-looking statement, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the aftereffects of COVID-19 pandemic and certain geopolitical tensions. Past performance is not necessarily a guide to future performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. Nothing contained in this presentation, or any other information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. None of the Company or any other Limited Party makes any representation or warranty as to the accuracy of any forward-looking statements contained in this presentation. Forward looking statements speak only as at the date of this presentation, and the Limited Parties disclaim any obligations or undertakings to release any update of, or revisions to, any forward-looking statements in this presentation.

Financial information contained in this presentation (if any) is unaudited, unless otherwise stated, and is therefore subject to change. You should be aware that this presentation has been prepared at a time when the review of the financial information contained in the presentation has not been completed and, accordingly, the Company takes no responsibility for, and can provide no assurance as to the reliability of, any information relating to the financial condition and/or financial and operating performance of the Company. Recipients of this presentation are cautioned therefore to not place any reliance on the financial (or other) information included in the presentation. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A\$) unless otherwise stated.

Certain market and industry data (including industry forecasts, projections, market sizes, market shares and market positions) included in this presentation has been obtained from public filings, research, surveys or studies conducted by third parties, including industry and general publications, which has not been independently verified by the Company, as well as from the Company's own internal estimates and research. The Company cannot warrant or guarantee the adequacy, fairness, accuracy or completeness of such information. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions. There is no assurance that any of the industry or market forecasts, including management estimates, which are referred to in this presentation will be achieved. In addition, such data involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. In addition, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source.

This presentation may contain trademarks and trade names of third parties, which are the property of their respective owners. Third party trademarks and trade names used in this presentation belong to the relevant owners and use is not intended to represent sponsorship, approval or association by or with the Company.

Agenda

Welcome & Chairman's Address

Formal Items of Business

- Resolutions & Questions

Closure of Annual General Meeting

CEO's Presentation

- 2024 Highlights
 - Recent Strategic Progress
 - Growth Pathway & Outlook
 - Q&A
-

Chairman's Address

Lawrence Gozlan, Chairman

Board And Executive Management

Board of Directors



Lawrence B. Gozlan

Board Chair, Non-Executive Director

Mr. Gozlan is the Chief Investment Officer and Founder of Scientia Capital and currently serves as a Director on several private and public company boards in Australia.



Sergio Duchini

Non-Executive Director

Sergio drives strategy and growth with a strong focus on customer, innovation, M&A and corporate governance by leveraging his knowledge and experience in strategy development & implementation, accounting & finance, corporate structuring and M&A.



Lisa Pettigrew

Non-Executive Director

Lisa has 25+ years experience in management consulting and technology services companies across multiple vertical industries, with a particular expertise in healthcare and life sciences.

Executive Management



Michael Sistenich

Executive Director & Chief Executive Officer

Michael has over 24 years of experience in the investment banking, corporate finance and asset management industry.



Darren Scotti

Chief Financial Officer and Company Secretary

Darren is a veteran CFO and board member with over two decades of experience managing capital.

Our Mission


Enlitic's mission is to revolutionise healthcare by leveraging AI and data, empowering evidence-based decision-making, enhancing research, and transforming healthcare delivery.

Industry Problems

Radiology departments are experiencing workflow and capacity challenges compounded by a **lack of data standardisation** that impacts data quality and stakeholders within the enterprise.

Staff within the radiology departments are experiencing **high rates of stress and burnout** resulting from increased workloads, increasing complexity of imaging studies and conflicting demands on time.

Millions of studies encompassing petabytes of data must be moved with a **low margin of error** and **meticulous management of migration timings** to ensure patient wellbeing.




Solution

The Enlitic solution is built upon a software framework, **creating a network between applications**. It houses an ecosystem that enables and supports the exchange of information or content between different interdependent applications.

The framework **facilitates communications** between modalities, Enlitic applications, Electronic Medical Records and PACS. It features a host of AI-powered applications that enable **data standardisation, de-identification, anonymisation and workflow simplification**.

Our healthcare **data migration** solution significantly reduces costs and timelines by securely preserving non-essential studies.

Transforming Care with Data and Technology




Meeting Procedures

Questions

Voting

Proxies

Resolutions



Resolution 1

Re-election of Class II Director – Michael Sistenich

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That Michael Sistenich, being eligible, offers himself for election, be elected a Director to hold office until the 2028 annual meeting of Stockholders.”

Summary of Proxies Voted Resolution 1	
For	170,024,381
Open	600
Against	0
Abstain	1

Resolution 2

Re-election of Class II Director – Sergio Duchini

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That Sergio Duchini, being eligible, offers himself for election, be elected a Director to hold office until the 2028 annual meeting of Stockholders.”

Summary of Proxies Voted Resolution 2	
For	170,024,381
Open	600
Against	0
Abstain	1

Resolution 3

Ratification of the Company’s accounting firm

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“To ratify selection by the Audit and Risk Committee of the Board of Directors of RSM Australia Pty Limited as independent registered public accounting firm of the Company for its fiscal year ending 31 December 2025.”

Summary of Proxies Voted Resolution 3	
For	170,024,381
Open	600
Against	1
Abstain	1

Resolution 4

Ratification of Common Stock (and corresponding CDIs) under Tranche 1 of the Placement

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That, for the purpose of Listing Rule 7.4 and for all other purposes, Stockholders ratify and approve the issue under Listing Rule 7.1 of 87,475,190 shares of Common Stock (and corresponding CDIs over such Common Stock) at A\$0.04 each to certain unrelated professional, sophisticated and other investors under Tranche 1 of the Placement on the terms and conditions set out in the Explanatory Memorandum.”

Summary of Proxies Voted Resolution 4

For	123,404,501
Open	600
Against	0
Abstain	1

Resolution 5

Proposed issue of Common Stock (and corresponding CDIs) under Tranche 2 of the Placement

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That, for the purpose of Listing Rule 7.1 and all other purposes, Stockholders approve the issue of up to 102,957,349 shares of Common Stock (and corresponding CDIs over such Common Stock) at A\$0.04 each to certain unrelated professional, sophisticated and other investors under Tranche 2 of the Placement on the terms and conditions set out in the Explanatory Memorandum.”

Summary of Proxies Voted Resolution 5

For	123,404,501
Open	600
Against	0
Abstain	1

Resolution 6

Proposed issue of Common Stock (and corresponding CDIs) to Mr Michael Sistenich (and/or his nominee(s)) under Tranche 2 of the Placement

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That, for the purpose of Listing Rule 10.11 and all other purposes, subject to Resolution 5 being passed, Stockholders approve the issue of up to 1,250,000 shares of Common Stock (and corresponding CDIs over such Common Stock) at A\$0.04 each to Mr Michael Sistenich (and/or his nominee(s)) under Tranche 2 of the Placement on the terms and conditions set out in the Explanatory Memorandum.”

Summary of Proxies Voted Resolution 6

For	167,924,382
Open	600
Against	2,100,000
Abstain	0

Resolution 7

Proposed issue of New Options

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That, for the purpose of Listing Rule 7.1 and all other purposes, Stockholders approve the issue of up to 124,375,000 New Options to certain unrelated professional, sophisticated and other investors, with each New Option having an exercise price of A\$0.05 and an expiry date of 3 years from the date of issue on the terms and conditions set out in the Explanatory Memorandum.”

Summary of Proxies Voted Resolution 7

For	121,302,091
Open	600
Against	2,102,410
Abstain	0

Resolution 8

Proposed issue of New Options to Mr Michael Sistenich (and/or his nominee(s))

To consider, if thought fit, to pass the following resolution as an ordinary resolution by the affirmative vote of a majority of the votes cast:

“That, for the purpose of Listing Rule 10.11 and all other purposes, subject to Resolution 7 being passed, Stockholders approve the issue of up to 625,000 New Options to Mr Michael Sistenich (and/or his nominee(s)), with each New Option having an exercise price of A\$0.05 and an expiry date of 3 years from the date of issue on the terms and conditions set out in the Explanatory Memorandum.”

Summary of Proxies Voted Resolution 8

For	167,921,971
Open	600
Against	2,102,411
Abstain	0

Resolution 9

Approval of Additional 10% Placement Capacity

To consider, if thought fit, to pass the following resolution as a special resolution by the affirmative vote of at least 75% of the votes cast:

"That, for the purpose of Listing Rule 7.1A and all other purposes, Stockholders approve the issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Memorandum."

Summary of Proxies Voted Resolution 9

For	168,271,971
Open	600
Against	1,752,410
Abstain	1

CEO Presentation

Michael Sistenich, CEO

What we do

Enlitic is a software development company that uses **artificial intelligence** to develop software products that manage medical imaging data in radiology and licences such products to healthcare providers.

Enlitic's 2024 acquisition of **Laitek**, one of the major providers of tech-enabled **healthcare data migration and routing services** in the United States, has expanded the Enlitic portfolio to include data migration capabilities.

Enlitic is at the forefront of **empowering healthcare providers** with its advanced data standardisation and AI-enabled solutions for medical imaging.

The progress Enlitic is making is reflected in the **pipeline growth** and business **relationships** it has developed, leveraging the 2024 acquisition of Laitek to aid in that growth.

2024 Highlights

129%

increase in revenue

Release of
Ensign 2.0
ahead of
schedule

Strategic
acquisition of
Laitek, Inc.

Pipeline strengthened
by acquisition
of Laitek, up

40.5%
on 2023

16

new agreements signed

***GE
HealthCare***

MSA Signed with
Laitek

US\$1.0m
in savings
through cost control
& synergies

Opportunity through technology



Laitek: Solving Complex Problems Efficiently

An essential component of the medical imaging ecosystem

TECH ENABLED DATA MIGRATION

THE PREMISE IS SIMPLE

The process of extracting, translating and loading archived medical imaging data from one source (legacy PACS) to another source (target PACS)

Reasons health systems typically undergo a migration

Internal Upgrades

Storage to cloud

Cost Savings

M&A Activity



THE REALITY: HIGHLY COMPLEX



Many millions of studies encompassing petabytes of data are needed to be moved



There is an extremely low margin of error and if performed incorrectly, may result in destruction of critical data



Meticulous management of migration timings is necessary otherwise the entire PACS can crash, severely impacting patient wellbeing



Extremely time consuming, often taking upwards of 12+ months to complete



The migration software can take 10+ years and millions of dollars to develop

Recent Business Highlights



Significant Commercial Progress

- Migration pipeline¹ grown by more than **US\$60m** since Laitek acquisition.
- Secured **US\$1.6m** (A\$2.6m) of new contract revenue to 23rd April 25, with 75% expected to be recognized in CY25.
- Additional **US\$0.6k** (A\$0.9m) of new contract value signed through end May 2025.
- Recognized Revenue in CY25 anticipated to be in the order of US\$9–\$11m (A\$14.5–\$17.5m)



Business Integration & Strategy

- Driving growth and capturing market share through AI Enabled Migrations.
- Technology integration incorporated into unified Product Roadmap.
- Cost and revenue synergies delivered ahead of expectations.



GE HealthCare Collaboration

- Executed binding MOU with GE HealthCare under which Laitek will work in good faith to deliver between **US\$3–6m per year** (A\$5–10m) of annual migration capacity to GEHC for next 5 years (i.e. potentially up to **US\$30m** (A\$50mn) of migration capacity).
- Foundational collaborator for GE HealthCare Genesis Cloud Product Suite.

1. The dollar values represent the Company's estimate (based on initial discussions and assessments with each potential customer) of TCV (the total contracted minimum licence revenue to be charged over the term (generally 3 years of contracts entered into with customers) of the contract), migration project revenue to be charged based on completion of milestones under the migration project, plus ancillary revenue (as applicable)) of each customer pipeline opportunity if every such opportunity was to result in a signed Licence Agreement (and the Company has assumed each such Licence Agreement has a term of 3 years) or having regard to the number and type of studies anticipated to be migrated in respect of relevant projects. There is no guarantee that any of the customer pipeline opportunities will result in any contracted clients or contracted revenue, and the dollar values indicated do not in any way represent an estimate of likely future revenue arising from those. It merely provides an indication of the potential size of the revenue opportunity presented by the customer pipeline opportunities.

GE HealthCare Relationship Formalized

GEHC Genesis Portfolio

GEHC announced a new cloud-suite of enterprise imaging solutions at HIMSS 2025.

- Designed to improve patient care coordination, reduce operational costs and maintain robust security standards.
- Enlitic is a foundational collaborator of this strategy with its AI-enabled data migration.
- Enlitic will streamline providers' transition from legacy on premise systems to modern infrastructures in the cloud.
- Ensign suite of data standardization and management tools will be onboarded and deployed through Amazon Web Services, a key partner.



Enlitic Combined Pipeline¹

Accelerating Revenue Targets via Advancing Key Pipeline Opportunities

Pipeline

		Pipeline Stage	No. of Contracts	Total Contract Value
Pipeline remains healthy and growing <ul style="list-style-type: none"> Focus on conversion and implementation. Integrations with OEMs will drive faster time to revenue. 	ENSIGHT	Pending Progression ²	37	\$32.0m
		Open Opportunity ³	95	\$55.6m
Significant growth across both OEM and Direct channels <ul style="list-style-type: none"> Enhanced Migrations with Data Standardisation well received by clients 	MIGRATION SERVICES	OEM Channel	36	\$70.6m
		Direct Channel	23	\$4.8m
Migration revenues opportunities well ahead of expectations <ul style="list-style-type: none"> Drive <i>Enlight</i> adoption to Migration customers. 	TOTAL	Enlight Pipeline	133	\$87.6m
		Migration Services Pipeline	59	\$75.4m
		Combined Pipeline	173	\$163.0m

All currency in USD

1. The dollar values represent the Company's estimate (based on initial discussions and assessments with each potential customer) of TCV (the total contracted minimum licence revenue to be charged over the term (generally 3 years of contracts entered into with customers) of the contract), migration project revenue to be charged based on completion of milestones under the migration project, plus ancillary revenue (as applicable)) of each customer pipeline opportunity if every such opportunity was to result in a signed Licence Agreement (and the Company has assumed each such Licence Agreement has a term of 3 years) or having regard to the number and type of studies anticipated to be migrated in respect of relevant projects. There is no guarantee that any of the customer pipeline opportunities will result in any contracted clients or contracted revenue, and the dollar values indicated do not in any way represent an estimate of likely future revenue arising from those. It merely provides an indication of the potential size of the revenue opportunity presented by the customer pipeline opportunities.

2. Pending Progression: Customers that have shown an initial interest in Enlitic's products but has placed the sales process on a temporary hold due to their own internal factors, such as, IT capacity or budget constraints.

3. Open Opportunity: Customers actively engaged with Enlitic in the sales process.

Our Pathway to Growth



Material interest in combined Ensign and Migration Services offerings

Active migration opportunities with PACS OEMs representing >60% of Global PACS market share.



Initial focus to lead with Migration services as fastest path to revenue

New migration services pipeline opportunities exceed US\$70m (A\$112m) over the next 3 years.



Integrating and strengthening our technological advantage

Integration of Enlitic's AI solutions continues to enhance our migration services offering.



Conversion of migration customers will drive future ARR growth

80% of Laitek OEM partners and end user customers are actively evaluating Ensign.



Summary & Outlook

Our strategic acquisition of Laitek has propelled our commercial progress

Our recently announced collaboration with GE HealthCare is evidence of our continued strategic progress to gain market share

Our combined offerings provide ongoing opportunities to strengthen our technological advantage and drive future ARR growth

Financials Outlook



- Recognized Revenue in CY2025 anticipated to be in the order of **US\$9-11m** (~A\$14.5-17.5m).
- Secured **US\$2.2m** (A\$3.5m) of new contract revenue in CY2025.
- Enlitic anticipates to achieve **operational cash flow break even** by the end of 2025.

Questions